GE HealthCare has announced a definitive agreement to acquire SOFIE Biosciences, a leading US-based CMO for PET radiopharmaceuticals, from Trilantic North America, for a purchase price of $945 million paid in cash.
The transaction is expected to close in the first half of 2027, subject to closing conditions, including regulatory approvals, at which time SOFIE Biosciences will become part of GE HealthCare’s PDx segment.
The acquisition of SOFIE Biosciences establishes a footprint for GE HealthCare in the time-critical ‘final mile’ of US PET radiopharmaceutical supply, while also enabling PDx to participate in other high growth areas outside its own product portfolio.
With a US network of 15 CMO sites operating 21 cyclotrons, and a theranostics-focused Contract Development and Manufacturing Organization (CDMO) site, this acquisition broadens GE HealthCare's footprint in the US radiopharmaceutical industry, while driving reliable patient access to novel radiopharmaceuticals.
It also further enables GE HealthCare’s ability to provide solutions along every step of the theranostics pathway, from cyclotrons to imaging technology, digital workflow tools and radiotherapeutics infrastructure.
PET radiopharmaceuticals are used in precision medicine to visualise metabolic and molecular activity and, increasingly, to deliver targeted therapies across a range of disease areas.
